RAIFFEISEN SWITZERLAND B.V. | Market Closed - Swiss Exchange 11:20:00 2024-06-21 am EDT | ||
| 101.8 CHF | -1.18% |
|
| 1 month | -0.62% | ||
| 3 months | +0.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
Static data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Raiffeisen Switzerland B.V. |
| MZBRCH | |
| ISIN | CH1282108898 |
| Date issued | 2023-09-15 |
| Strike | 575.7 $ |
| Maturity | 2025-03-18 (262 Days) |
| Parity | 1 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | both |
| Currency | CHF |
Technical Indicators
| Highest since issue | 103.2 CHF |
|---|---|
| Lowest since issue | 96.2 CHF |
| Spread | 8.1 CHF |
| Spread % | 0.79% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- MZBRCH Certificat
